Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
2.696
+0.106 (4.09%)
Nov 29, 2024, 12:57 PM EST - Market closed
Company Description
Medicus Pharma Ltd., a biotech/life sciences company, focuses on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers.
It is developing SkinJect with an indication for basal cell carcinoma. The company is headquartered in Toronto, Canada.
Medicus Pharma Ltd.
| Country | Canada |
| Founded | 2008 |
| Industry | Other |
| CEO | Raza Bokhari |
Contact Details
Address: One First Canadian Place, Suite 3400 Toronto, ON M5X 1A4 Canada | |
| Phone | 610-636-0184 |
| Website | medicuspharma.com |
Stock Details
| Ticker Symbol | MDCX |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001997296 |
| ISIN Number | CA58471K2020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Raza Bokhari | Chief Executive Officer |
| James Quinlan | Chief Financial Officer |
| Erica Monaco | Chief Operating Officer |
| Viktoriia Slepeniuk | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 25, 2024 | 424B3 | Prospectus |
| Nov 25, 2024 | 6-K | Report of foreign issuer |
| Nov 18, 2024 | 6-K | Report of foreign issuer |
| Nov 18, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | 424B4 | Prospectus |
| Nov 14, 2024 | CERT | Certification by an exchange approving securities for listing |
| Nov 14, 2024 | 8-A12B | Registration of securities |
| Nov 13, 2024 | EFFECT | Notice of Effectiveness |
| Oct 31, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Oct 29, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |